Period 1 | Period 2 | ||
---|---|---|---|
Drug | No. | Drug | No. |
Antibiotics | 5 (20.8%) | NSAIDs | 107 (31.7%) |
Cephalosporin | 2 | Conventional | 97 |
Lincosamide | 1 | Cox-2 inhibitor | 10 |
Sulfa | 1 | Antibiotics | 35 (10.4%) |
Cytotoxicity | 1 | Cephalosporin | 13 |
Antilipemics | 3 (12.5%) | Quinolone | 18 |
Plasma expander | 3 (12.5%) | Lincosamide | 4 |
BAs | 2 (8.3%) | Cardiovascular | 34 (10.1%) |
CNS drugs | 2 (8.3%) | Antihypertensive | 22 |
Chinese patent medicine | 1 (4.2%) | Antilipemic | 5 |
ACEI/ARB | 1 (4.2%) | Antiarrhythmic | 4 |
Antithrombotic | 1 (4.2%) | Nitrates | 1 |
Endocrine | 1 (4.2%) | Cardiotonic | 2 |
Immunoregulation | 1 (4.2%) | Chinese patent medicine | 27 (8.0%) |
Others | 4 (16.7%) | Antithrombotic | 22 (6.5%) |
CNS drugs | 18 (5.3%) | ||
Endocrine | 17 (5.0%) | ||
PPI | 11 (3.3%) | ||
Hormone | 8 (2.4%) | ||
Others | 59 (17.5%) |